Arbutus reports second quarter 2021 financial results and provides corporate update

New data on ab-729, arbutus' proprietary subcutaneously delivered rnai agent, highlighted in four abstracts at the easl international liver congress™ ; all ab-729 abstracts selected for best of ilc™

ABUS Ratings Summary

ABUS Quant Ranking